Group 1 - The CRO concept sector has seen a significant rise, with companies like Lianhua Technology (002250) hitting the daily limit up, indicating strong investor interest [1] - Ruizhi Pharmaceutical (300149) has increased by over 10%, reflecting positive market sentiment towards the CRO sector [1] - Other companies such as Meinuohua (603538), Jinkai Biotechnology (301509), Shengnuo Biotech, Wanbang Pharmaceutical (301520), and Haoyuan Pharmaceutical have also experienced gains, showcasing a broader trend in the industry [1]

Group 1 - Weijie Chuangxin plans to reduce its shareholding by up to 3%, amounting to no more than 12.91 million shares, due to personal funding needs [1] - Lier Chemical's major shareholder intends to reduce its stake by up to 3%, equivalent to no more than 24.01 million shares, for investment returns [1] - Helin Micro-Nano's controlling shareholder plans to reduce its shareholding by up to 1.5%, which is no more than 1.75 million shares, due to personal funding needs [2] Group 2 - Yifan Pharmaceutical received drug registration certificates for two products, indicating a focus on oncology and leukemia treatments [3] - *ST Jinbi is planning a change in control, leading to a temporary suspension of its stock trading [4] - Kexing Pharmaceutical's shareholder plans to reduce its stake by up to 3%, amounting to no more than 5.90 million shares, to optimize the equity structure [7] Group 3 - Li New Energy plans to invest approximately 1.25 billion yuan in three independent energy storage projects [7] - Kingsoft Office intends to acquire the remaining 31.98% stake in its subsidiary for 254 million yuan, aiming for full ownership [8] - Northeast Pharmaceutical received a CEP certificate from the European Medicines Agency for an antibiotic raw material, enhancing its product credibility [9] Group 4 - Tai'er Co. announced the lifting of a detention order on its controlling shareholder, changing it to a notice of supervision [10] - Runjian Co. won a bid for a solar power project worth approximately 83.92 million yuan, highlighting its role in the energy sector [11] - Jiuan Medical plans to register and issue medium-term notes and short-term financing bonds, with a total scale of up to 35 billion yuan and 5 billion yuan respectively [12] Group 5 - Wanma Co.'s chairman resigned due to work adjustments, but will remain as a board member [13] - Changhua Chemical plans to transfer 1% of its shares through an inquiry transfer method due to personal funding needs [14] - Jinkai Biotechnology's two shareholders plan to reduce their combined stake by up to 4%, totaling 481.6 thousand shares [15] Group 6 - Aeston plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [16] - Maiwei Biotechnology's chairman proposed a share buyback plan with a total amount between 25 million and 50 million yuan [17] - Montai High-tech's specific shareholders and executives plan to reduce their stake by up to 3.03%, citing personal funding needs [18] Group 7 - *ST Dongjing's stock will resume trading after a change in control, with a new actual controller [20] - Tongdahai's major shareholders plan to reduce their combined stake by up to 3.57%, totaling 345.24 thousand shares [23]

金凯生科股东青松投资持有公司股份4,801,374股(占公司总股本比例3.99%)。青松投资计划通过集中竞 价方式减持公司股份不超过1,204,000股，减持比例不超过公司总股本的1%。集中竞价的减持期间为自 本减持计划公告之日起十五个交易日后的三个月内。 中国经济网北京6月5日讯金凯生科（301509）(301509.SZ)昨晚披露的关于公司股东减持股份的预披露 公告显示，公司于近日分别收到股东启鹭(厦门)股权投资合伙企业(有限合伙)(以下简称"启鹭投资")、青 岛青松创业投资集团有限公司-青岛松凯创业投资企业(有限合伙)(以下简称"青松投资")提交的《关于减 持金凯(辽宁)生命科技股份有限公司股份计划的告知函》。 金凯生科股东启鹭投资持有公司股份7,140,500股(占公司总股本比例5.93%)。启鹭投资计划通过集中竞 价和大宗交易方式减持公司股份不超过3,612,000股(占公司总股本比例3%)。其中，通过集中竞价方式减 持股份不超过1,204,000股，减持比例不超过公司总股本的1%；通过大宗交易方式减持股份不超过 2,408,000股，减持比例不超过公司总股本的2%。集中竞价或大宗交易的减持期间为自 ...

Core Viewpoint - The A-share medical service sector experienced a short-term decline, with significant drops in several companies' stock prices, indicating potential market volatility in this industry [1] Company Summary - Jinkai Biotechnology saw a decline of over 8% in its stock price [1] - Other companies that followed the downward trend include Sunshine Nuohuo, Tigermed, Hongbo Pharmaceutical, Berry Genomics, and Chengdu Xian Dao [1]

Group 1 - The healthcare sector has experienced a short-term decline, with Jinkai Biotechnology (301509) dropping over 8% [1] - Other companies such as Hongbo Pharmaceutical (301230), Baicheng Pharmaceutical (301096), Chengdu XianDao, and Wanbang Pharmaceutical (301520) also saw declines [1] - There is a notable influx of dark pool capital into these stocks, indicating potential interest from institutional investors [1]

Core Viewpoint - Shareholders Qilu Investment and Qingsong Investment plan to collectively reduce their holdings by no more than 4% of the company's shares [1] Summary by Relevant Categories Shareholder Actions - Qilu Investment intends to reduce its stake by up to 3%, with a maximum of 1% through centralized bidding and 2% via block trading [1] - Qingsong Investment plans to reduce its stake by up to 1% through centralized bidding [1] Timeline - The reduction period will be within three months starting from fifteen trading days after the announcement date [1]

Group 1 - The core point of the announcement is that shareholders Qi Lu Investment and Qingsong Investment plan to reduce their holdings in Jinkai Biotechnology (301509) by a total of up to 361.2 million shares, which represents 3% of the company's total share capital [1] - Qi Lu Investment intends to reduce its stake by up to 120.4 million shares through centralized bidding, accounting for 1% of the total share capital, and by up to 240.8 million shares through block trading, accounting for 2% of the total share capital [1] - Qingsong Investment plans to reduce its stake by up to 120.4 million shares through centralized bidding, also representing 1% of the total share capital [1] Group 2 - The reduction period for these share sales will be within three months starting from fifteen trading days after the announcement date [1]

金凯（辽宁）生命科技股份有限公司 关于公司股东减持股份的预披露公告 股东启鹭（厦门）股权投资合伙企业（有限合伙）、青岛青松创业投资集团 有限公司－青岛松凯创业投资企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）股东启鹭（厦门）股权 投资合伙企业（有限合伙）（以下简称"启鹭投资"）持有公司股份7,140,500股（占 公司总股本比例5.93%）。启鹭投资计划通过集中竞价和大宗交易方式减持公司股份不 超过3,612,000股（占公司总股本比例3%）。其中，通过集中竞价方式减持股份不超过 1,204,000股，减持比例不超过公司总股本的1%；通过大宗交易方式减持股份不超过 2,408,000股，减持比例不超过公司总股本的2%。集中竞价或大宗交易的减持期间为自 本减持计划公告之日起十五个交易日后的三个月内。 公司股东青岛青松创业投资集团有限公司－青岛松凯创业投资企业（有限合伙） （以下简称"青松投资"）持有公司股份4,801,374股（ ...

Market Overview - As of June 3, the Shanghai Composite Index closed at 3361.98 points, up 14.49 points, with a gain of 0.43% [1] - The Shenzhen Component Index closed at 10057.17 points, up 16.54 points, with a gain of 0.16% [1] - The ChiNext Index closed at 2002.70 points, up 9.51 points, with a gain of 0.48% [1] High Turnover Stocks - A total of 78 A-shares had a turnover rate exceeding 20% on June 3 [1] - Notable stocks with high turnover rates include: - Xiongdi Technology (300546) with a turnover rate of 61.20% and a closing price of 25.18 yuan, up 0.72% [1] - New World (301277) with a turnover rate of 51.25% and a closing price of 17.55 yuan, up 11.01% [1] - Kangliyuan (301287) with a turnover rate of 43.10% and a closing price of 37.70 yuan, up 12.98% [1] Additional High Turnover Stocks - Other stocks with significant turnover rates include: - C Guqi (001390) at 42.61% turnover, closing at 25.65 yuan, down 5.07% [1] - Guangkang Biochemical (300804) at 42.51% turnover, closing at 44.68 yuan, up 5.75% [1] - Wangzi New Materials (002735) at 42.39% turnover, closing at 17.70 yuan, down 10.02% [1] Summary of Turnover Rates - The data indicates a trend of increased trading activity in certain stocks, with several companies experiencing significant fluctuations in their share prices alongside high turnover rates [1][2][3]

证券代码：301509 证券简称：金凯生科 公告编号：2025-017 金凯（辽宁）生命科技股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"或"发行人"） 2024年年度权益分派方案已获2025年5月19日召开的2024年度股东会审议通过，现 将权益分派事宜公告如下： 一、股东会审议通过的利润分配方案情况 1、公司2024年度利润分配方案为：以截至2024年12月31日公司总股本 120,446,669股为基数，向全体股东每10股派发现金红利人民币4.00元（含税）， 合计派发现金红利人民币48,178,667.60元（含税）；不送红股；资本公积金不转 增股本；剩余未分配利润结转至以后年度。本次利润分配完成后，本年度累计现 金分红总额48,178,667.60元，占公司本年度合并报表归属于母公司所有者净利润 的124.79%。 率征收，本公司暂不扣缴个人所得税，待个人转让股票时，根据其持股期限计算 应纳税额【注】；持有首发后限售股、股权激励限售股及无限售流通股的证券 ...